Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape
oncodaily - Bristol Myers Squibb (NYSE: BMY) and Jiangsu Hengrui Pharma (600276.SH; 01276.HK) on Tuesday unveiled one of the largest cross-border biopharma collaborations of the year: a global strategic alliance encompassing 13 […]
AI Summary: Bristol Myers Squibb and Hengrui Pharma announced a sweeping strategic alliance covering multiple oncology assets, with potential payments and milestones that could reach roughly $15.2 billion. The deal bundles discovery, development and commercialization rights, reshaping China‑out‑licensing dynamics and signaling continued consolidation and collaboration in global cancer drug development.
Related Stories
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 2 months
Datroway secures regulatory approvals in breast cancer across US and EU / 3 months
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month
Teclistamab shows survival benefit prompting earlier use discussions / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Health IT, FDA, Infectious Disease, Pancreatic Cancer and look for the RSS link.
StackHealth Time Machine